OmniAb (OABI) Cash from Operations (2021 - 2026)
OmniAb (OABI) reported Cash from Operations of 4914000.0 for Q1 2026, up 69.04% year-over-year from 2907007.38 in Q1 2025, and up 13.39% on a QoQ basis from 5674000.0 in Q4 2025.
OmniAb (OABI) has 6 years of Cash from Operations data on file, last reported at 4914000.0 in Q1 2026.
- Quarterly Cash from Operations rose 69.04% year-over-year to 4914000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 25497000.0 (up 33.78% YoY) and the FY2025 annual result came in at 36455000.0, up 8.09% from the prior year.
- Cash from Operations advanced to 4914000.0 in Q1 2026 per OABI's latest filing, from 5674000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 27688000.0 in Q1 2023 and bottomed at 17032000.0 in Q1 2024.
- The 5-year median for Cash from Operations is 6198000.0 (2023), against an average of 4839588.24.
- The widest annual swing landed in 2022, when Cash from Operations plunged 337.92%; it then surged 137.87% in 2023.
- Tracing OABI's Cash from Operations over 5 years: stood at 7143000.0 in 2022, then declined by 27.69% to 9121000.0 in 2023, then jumped by 57.55% to 3872000.0 in 2024, then slumped by 46.54% to 5674000.0 in 2025, then grew by 13.39% to 4914000.0 in 2026.
- Per Business Quant, the three latest OABI Cash from Operations figures stand at 4914000.0 (Q1 2026), 5674000.0 (Q4 2025), and 9763000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | -4.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.91 Mn |
| Mar 31, 2026 | -4.91 Mn |
| Dec 31, 2025 | -5.67 Mn |
| Dec 31, 2025 | -5.67 Mn |
| Sep 30, 2025 | -9.76 Mn |
| Sep 30, 2025 | -9.76 Mn |
| Jun 30, 2025 | -5.15 Mn |
| Jun 30, 2025 | -5.15 Mn |
| Mar 31, 2025 | -15.87 Mn |
| Mar 31, 2025 | -15.87 Mn |
| Dec 31, 2024 | -3.87 Mn |
| Dec 31, 2024 | -3.87 Mn |
| Sep 30, 2024 | -6.58 Mn |
| Sep 30, 2024 | -6.58 Mn |
| Jun 30, 2024 | -12.18 Mn |
| Jun 30, 2024 | -12.18 Mn |
| Mar 31, 2024 | -17.03 Mn |
| Mar 31, 2024 | -17.03 Mn |
| Dec 31, 2023 | -9.12 Mn |
| Dec 31, 2023 | -9.12 Mn |
| Sep 30, 2023 | -6.20 Mn |
| Sep 30, 2023 | -6.20 Mn |
| Jun 30, 2023 | -10.02 Mn |
| Jun 30, 2023 | -10.02 Mn |
| Mar 31, 2023 | 27.69 Mn |
| Mar 31, 2023 | 27.69 Mn |
| Dec 31, 2022 | -7.14 Mn |
| Dec 31, 2022 | -7.14 Mn |
| Sep 30, 2022 | -4.23 Mn |
| Sep 30, 2022 | -4.23 Mn |
| Jun 30, 2022 | -3.85 Mn |
| Jun 30, 2022 | -3.85 Mn |
| Mar 31, 2022 | 11.64 Mn |
| Mar 31, 2022 | 11.64 Mn |
| Dec 31, 2021 | -4.71 Mn |
| Dec 31, 2021 | -4.71 Mn |
| Sep 30, 2021 | -966,377.00 |
| Sep 30, 2021 | -966,377.00 |